CAR T-cell therapy made from your own immune cells
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests an “autologous” CAR T-cell treatment (made from your own T cells) that targets a cancer marker called CD79b in certain relapsed or hard-to-treat B-cell lymphomas. It’s designed to find a safe dose and see whether the treatment can shrink tumors and help control the lymphoma after prior therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older, and you can do most daily activities (ECOG 0–1).
- Your lymphoma is a relapsed or refractory B-cell type, such as DLBCL, follicular lymphoma, mantle cell, marginal zone, or transformed forms (details vary by study “dose phase”).
- You’ve already tried enough prior treatments (at least 2 lines for most types; Burkitt usually needs at least 1 line).
- You must have at least one measurable tumor spot on scans, and enough time must have passed since your last cancer treatment (typically 2 weeks or 5 half-lives; longer for some antibody drugs).
- Your blood and organ tests must meet thresholds (neutrophils, lymphocytes, platelets, kidney function, liver enzymes, oxygen levels, and heart pumping function).
- If you had prior CAR T therapy targeting CD19 (using the FMC63 antibody), you may qualify only if at least 6 weeks have passed and a small number of those CAR T cells remain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
This trial tests a new treatment using your own immune cells, called CAR T cells, that are specially made to find and attack cancer cells in B-cell lymphoma. It may help if your lymphoma has come back or has not gone away after other treatments.
This Phase 1/2 study tests a customized type of immune cell treatment (CD19 CAR T-cells) for people with certain relapsed or hard-to-treat lymphomas or CLL/SLL. It aims to improve control of disease by targeting the CD19 marker on cancer cells.
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
Hear when a new Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.